Navigation Links
ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
Date:3/26/2008

Live Webcast and Conference Call Scheduled for Monday, March 31st at 5 PM

ET

TUCSON, Ariz., March 26 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company has rescheduled a live webcast and conference call, which will now take place on Monday, March 31, 2008, at 5:00 p.m. ET to discuss corporate updates and financial results for the fourth quarter and full year 2007.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407- 4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through April 8, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 279436).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its FDA approved product, urokinase, for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

646-536-7002 or 7025

sephraim@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. New Edition of Definitive Resource in Tissue Engineering Released Today
4. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
5. Instant JChem 2.0 Released: Instant JChem Personal Free for All Users
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
8. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
9. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 14, 2007; Conference Call set for 1:00 p.m. ET
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox ... response to client demand KbioBox developed a sophisticated “3 click” gene dditing off ... accessible from KBioBox’s new website, https://www.kbiobox.com/ and powered by the ...
(Date:12/8/2016)... ... ... This CAST literature review and report looks at problems caused by the current ... in countries that are major global commodity exporters and importers, which show that asynchrony ... level presence (LLP) puts large volumes of trade worth billions of dollars at risk. ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
Breaking Biology Technology:
(Date:11/29/2016)... 2016   Neurotechnology , a provider ... technologies, today released FingerCell 3.0, a software ... that run on low-power, low-memory microcontrollers. FingerCell ... than 128KB of memory, enabling it to ... limited on-board resources, such as: mobile phones, ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
Breaking Biology News(10 mins):